21.07.05

21.7.2005: Meldung: Baxter Healthcare Corporation to Distribute and Promote Gambro"s Hemodialysis Instruments

Baxter Healthcare Corporation announced today it has entered into an agreement with Gambro Renal Products to distribute and promote Gambro"s hemodialysis (HD) instruments worldwide. The company has concluded separately that it would discontinue the manufacture of HD instruments, however, current customers will continue to receive full support for the Baxter instruments in use in the field today. These decisions allow Baxter to continue to provide a complete and competitive in-center HD product offering, while further advancing its home therapy business, including peritoneal dialysis (PD), worldwide.

The agreement with Gambro is consistent with the company"s strategy to optimize and improve the performance of its HD business while maintaining a broad portfolio of HD products for renal patients around the world. Baxter will now distribute Gambro"s HD instruments and directly related ancillary products through the new distribution and promotion agreement. The company will continue to distribute its existing line of HD dialyzers, and provide HD solutions and concentrates that are manufactured by Baxter. This new approach enables Baxter to continue to focus internal product development resources on home therapies, drawing on its strengths in PD. Financial terms of the agreement were not disclosed.

"After considering our strategic alternatives, we are pleased to announce a distribution and promotion agreement with Gambro, a global leader in HD instrumentation," said Bruce McGillivray, corporate vice president and president of Baxter"s Renal business. "This agreement will allow us to further build on our strong home therapy expertise, leveraging our global leadership position in PD, while we continue meeting the in-center needs of our customers."

Baxter will have exclusive distribution rights for Gambro HD instruments throughout most of Latin America, and a non-exclusive distribution and promotion arrangement in the United States and the rest of the world, excluding Japan where Baxter does not participate in the HD market. In non-exclusive countries, Baxter and Gambro will each sell HD instruments and directly related ancillary products through their respective sales channels. Baxter will continue to provide customer service and spare parts support for its existing HD instrument base.

"We remain extremely committed to our customers and to the renal community," McGillivray added. "We will ensure that our current HD customers continue to receive support for the HD instruments that they have purchased from Baxter, while we make a seamless transition to Gambro"s instruments."

In connection with this agreement and the company"s decision to discontinue hemodialysis instrument manufacturing, the company expects to record a pre-tax charge in future quarters totaling $40 to $50 million.

Baxter Healthcare Corporation is a subsidiary of Baxter International. Baxter International, through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients" lives.

This news release contains forward-looking statements within the meaning of the federal securities laws. These statements involve risks and uncertainties, including: the company"s ability to realize in a timely manner the anticipated benefits of restructuring initiatives; the effect of economic conditions; the impact of geographic and/or product mix on the company"s sales; actions of regulatory bodies and other governmental authorities, including the Food and Drug Administration and foreign counterparts that could delay, limit or suspend product sales and distribution; product quality and/or patient safety concerns leading to product recalls, withdrawals, launch delays or declining sales; product development risks; interest rates; technological advances in the medical field; demand for and market acceptance risks for new and existing products, and other technologies; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; inventory reductions or fluctuations in buying patterns by wholesalers or distributors; foreign currency exchange rates; the availability of acceptable raw materials and component supply; global regulatory, trade and tax policies; the ability to enforce patents; patents of third parties preventing or restricting the company"s manufacture, sale or use of affected products or technology; reimbursement policies of government agencies and private payers; internal and external factors that could impact commercialization; results of product testing; and other risks detailed in the company"s filings with the Securities and Exchange Commission. These forward-looking statements are based on estimates and assumptions within the bounds of management"s knowledge of the company"s business and operations, but there can be no assurance that the actual results or performance of the company will conform to any future results or performance expressed or implied by such forward-looking statements, and undue reliance should not be placed on them. Actual results could differ materially from such statements. Please refer to Baxter"s Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and other documents filed by the company with the Securities and Exchange Commission, which are also available on Baxter"s website, for more details concerning important factors that could cause actual results to differ materially. The company disclaims any current intention to update any forward-looking statements and all such statements speak only as of the time when made.

Contact:
Baxter Healthcare Corporation
One Baxter Parkway
Deerfield, IL 60015-4625
847-948-2000
Nach oben scrollen
ECOreporter Journalistenpreise
Anmelden
x